Search
Branaplam
go.drugbank.com/drugs/DB14918InvestigationalBranaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).
Pilocarpine
go.drugbank.com/drugs/DB01085ApprovedInvestigationalA naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist. Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine ...
VM4-037
go.drugbank.com/drugs/DB15319InvestigationalVM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalIn Europe, Hexaminolevulinate is marketed under the brand Hexvix®.
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawn[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Thiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigationalThiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, ...
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIt is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and